Wells Fargo & Company Lowers NovoCure (NASDAQ:NVCR) Price Target to $42.00

NovoCure (NASDAQ:NVCR – Get Free Report) had its target price lowered by investment analysts at Wells Fargo & Company from $49.00 to $42.00 in a research report issued on Wednesday, Benzinga reports. The firm presently has an “overweight” rating on the medical equipment provider’s stock. Wells Fargo & Company‘s price objective indicates a potential upside […]

Related Keywords

Japan ,United States ,Germany ,China ,Optune Gio ,Optune Lua ,Frankx Leonard ,Jpmorgan Chase Co ,China Universal Asset Management Co ,Unisuper Management Pty Ltd ,Us Bancorp ,Securities Exchange Commission ,Novocure Company Profile ,Wells Fargo Company ,Get Free Report ,Wells Fargo ,Exchange Commission ,Super Management Pty Ltd ,Universal Asset Management ,Cure Limited ,Greater China ,Novocure Daily ,Novocure ,Nasdaq Nvcr ,Nvcr ,Medical ,Lower Price Target ,